JOURNAL

JOURNAL

JOURNAL

2018/08/20CONFERENCE

WCLC 2018, Toronto

World Conference on Lung Cancer 2018 (WCLC) 23-26 September 2018, Toronto, Canada

2017/03/01CONFERENCE

BSH 2017

British Society for Haematology Annual Scientific Meeting 27-29 March 2017, Brighton

2016/04/06CONFERENCE

ITS 2016

Irish Thoracic Society Annual Scientific Meeting | 18 - 19 November 2016 | Fitzpatrick Castle Hotel, Killiney, Co Dublin. http://irishthoracicsociety.com/  

2015/11/10INDUSTRY NEWS

New study provides insights into potential treatment of severe pain in Parkinson’s disease with prolonged-release oxycodone/naloxone

Dublin, 10 November 2015 - A study published in The Lancet Neurology has provided important insights into the analgesic effects of prolonged release oxycodone/naloxone (OXN PR) for Parkinson’s disease patients with chronic, severe pain.[1]   The primary endpoint of improved average 24-hour pain score with OXN PR versus placebo at week 16 was not met (p=0.058), however assessments at other time points as well as secondary endpoint data indicate some potentially positive treatment effects with OXN PR.[1]

2015/02/25INDUSTRY NEWS

Oral OTEZLA® (apremilast) Approved in the EU for the Treatment of Plaque Psoriasis and Psoriatic Arthritis

Plaque Psoriasis:   OTEZLA® is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). _____________________________________________________________________   Psoriatic Arthritis:   OTEZLA®  is indicated alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.